Ferramentas Pessoais
Você está aqui: Entrada Notícias Paula Alves

Paula Alves

HCP_EIS2018_PAlves.jpg

 

 

 
Paula Alves
CEO, iBET

ABOUT THE SPEAKER:

Paula Alves is the CEO of iBET, the Head of the Animal Cell Technology Unit and Professor at the NOVA University (ITQB and FCT).  She received her Ph.D. at Biochemical Engineering from the NOVA University of Lisbon in 2001 and her B.S in Biochemistry from the Sciences Faculty of the University of Lisbon in 1991. Professor Alves research group integrates cell metabolism understanding with biochemical engineering for the improvement of bioprocesses efficiency and is focused at developing new tools and technologies for pre-clinical research. The Unit she coordinates uses Animal Cell Technology for research and development in particular for (i) production of complex biopharmaceuticals such as viral vectors, vaccines and recombinant proteins (ii) development of 3D culture systems for toxicity testing using primary cells and stem cells in bioreactors (iii) expand systems biology approaches to organize the complexity of the processes involved in the research described in (i) and (ii).  She is currently the President of the ESACT, the European Society for Animal Cell Technology and Member of the Advisory Group for Horizon 2020 Societal Challenge 1- European Commission. Paula Alves has published over 230 papers, 30 book chapters and supervised 25 PhD students.

 

ABOUT THE PRESENTATION:

"Pluripotent Stem Cells for Drug Development and Cell Therapy"

Human pluripotent Stem Cells (hPSC) have an enormous potential as a source for cell replacement therapies, tissue engineering, and in vitro toxicology applications. The lack of standardized and robust bioprocesses for their expansion and analytical tools for their characterization has hindered the application of PSC in clinical settings and as alternative cell sources for in vitro cell models used in pre-clinical research. In our lab we've been developing 3D cell culture strategies for the production of hPSC exploiting the potential of GMP compatible and scalable bioreactor technology together with the application of -omic tools for characterization of the cell-based products. Our main achievements and the hurdles we face to translate our findings to industrial sets and to clinics will be discussed.

 

[voltar ao programa | back to the programme]